Abstract Details

Title Ischemic Stroke in Neurosarcoidosis: a Retrospective Cohort Analysis

Topic Autoimmune Neurology

Presentation(s) C4 - Neurologic Manifestations of Rheumatologic Disease (9:20 AM-9:25 AM)
P2 - Poster Session 2 (9:00 AM-3:00 PM)

Poster/Presentation
Number 059

Objective To provide a detailed analysis of the clinical features and course of ischemic stroke secondary to sarcoidosis of the CNS and to observe the effects of immunosuppression in the prevention of recurrent cerebrovascular disease.

Background Cerebrovascular disease is rarely reported in neurosarcoidosis and constitutes one of its least well-described forms, though recognition for it has grown in the last decade with recent studies estimating a higher frequency of occurrence than previously known.

Design/Methods Patients with ischemic stroke were included if the mechanism was directly attributable to sarcoidosis of the CNS. Patients were excluded if an alternative stroke etiology was of equal or higher likelihood than CNS sarcoidosis.

Results Neurologic disease was the initial presenting manifestation of sarcoidosis in 8/11 (72.7%), and ischemic stroke was an inaugural manifestation of sarcoidosis in 4/11 (36.4%). Small vessel disease was the predominant ischemia subtype (10/11, 90.9%) with pontine perforating vessels (6/11, 54.5%) and lenticulostriate arteries (3/11, 27.3%) being the vessels most often affected. Vessels with a more rostral supratentorial distribution were uncommonly affected. Common neuroinflammatory accompaniments included leptomeningitis (10/11, 90.9%) and cranial nerve disease (4/11, 36.4%). Recurrent strokes occurred in 8/11 (72.7%), and recurrent neuroinflammation occurred in 7/11 (63.6%). Antiplatelet drugs were used in 6/11 (54.5%). Most patients (10/11, 90.9%) required at least two lines of immunosuppression to achieve inflammatory disease remission in this context; infliximab was the most successfully employed immunosuppressant (7/8 treatment courses, 87.5%). The presenting median modified Rankin Scale score of 4.0 improved to 2.0 over a median period of follow-up of 52.0 months.

Conclusions Ischemic strokes in neurosarcoidosis occur in a caudal-to-rostral distribution, tend to affect small caliber blood vessels that lack collateral blood flow, and typically associate with inflammatory leptomeningeal disease.

Authors/Disclosures
Spencer Hutto, MD (Emory University: Neurology Residency Program) PRESENTER	Dr. Hutto has nothing to disclose.
Kevin J. Kyle, MD (Massachusetts General Hospital)	Dr. Kyle has nothing to disclose.
Denis T. Balaban, MD (Massachusetts General Hospital)	Dr. Balaban has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Infucare. The institution of Dr. Balaban has received research support from ArgenX.
Nagagopal Venna, MBBS, FAAN (Massachusetts General Hospital)	Dr. Venna has nothing to disclose.

��ɫ��

��ɫ��